ERBB2 and cancer: To date, we know that DTCs can adapt to different microenvironments, reside in a non-proliferate (Ki67-negative) state, express oncogenes such as HER2, develop resistance against systemic anti-cancer treatment as well as acquire cancer stem cell (CSC)-like traits [9–11].